Brenda Wyrick
Family · Waxahachie, TXNPI 1356375364
Payments from drug & device makers
Across 335 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$970
- Boehringer Ingelheim$848
- Regeneron Healthcare Solutions, Inc.$729
- Insmed, Inc.$583
- Sanofi$440
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,51199%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $1,222 |
| AstraZeneca | 52 | $970 |
| Boehringer Ingelheim | 39 | $848 |
| Regeneron Healthcare Solutions, Inc. | 24 | $729 |
| Insmed, Inc. | 31 | $583 |
| Sanofi | 14 | $440 |
| Mylan Specialty L.p. | 26 | $402 |
| Amgen | 11 | $200 |
| Mallinckrodt Hospital Products Inc. | 6 | $185 |
| Actelion Pharmaceuticals US, Inc. | 5 | $167 |
| Novartis | 9 | $147 |
| Paratek Pharmaceuticals, Inc. | 4 | $87 |
| United Therapeutics Corporation | 3 | $83 |
| Electromed, Inc. | 4 | $76 |
| Sunovion Pharmaceuticals Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Harmony Biosciences LLC | 3 | $59 |
| Merck | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Gilead | 2 | $30 |
| Inogen, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,605 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 142 | $98,379 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $74,512 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $32,935 |
| Spiriva RespimatTiotropium Bromide | 54 | $29,424 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $20,773 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $19,650 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $7,674 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 298 | $6,956 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,225 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,750 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,927 |
| Montelukast Sodium | 192 | $1,312 |
| Roflumilast | 16 | $1,084 |
| Fluticasone Propionate | 84 | $1,005 |
| Azelastine Hcl | 39 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,222 | $138,802227 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $970 | $78,736119 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $848 | $62,359108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Waxahachie
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.